Substituted naphthyridinone derivatives

Details Substituted naphthyridinone derivatives Substituted naphthyridinone derivatives

2004-10-29

2010-06-01

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S300000

Reexamination Certificate

active

07728141

ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

REFERENCES:
patent: 6344474 (2002-02-01), Maruani et al.
patent: 2004/0214838 (2004-10-01), Carpino et al.
patent: 2004/0214855 (2004-10-01), Carpino et al.
patent: 2004/0214856 (2004-10-01), Carpino et al.
patent: 2004/0248881 (2004-12-01), Carpino et al.
patent: 2005/0085493 (2005-04-01), Brain et al.
patent: 2005/0143381 (2005-06-01), Yu et al.
patent: 2005/0203112 (2005-09-01), Castonguay et al.
patent: 2005/0272763 (2005-12-01), Toupence et al.
patent: 2006/0094714 (2006-05-01), Bullock et al.
patent: 1 142 877 (2001-10-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 03/086394 (2003-10-01), None
patent: WO 2004/060882 (2004-07-01), None
patent: WO 2004/087704 (2004-10-01), None
patent: WO 2005/103052 (2005-01-01), None
patent: WO 2005/021547 (2005-03-01), None
patent: WO 2005/035532 (2005-04-01), None
patent: WO 2005/049615 (2005-06-01), None
patent: WO 2005/061504 (2005-07-01), None
patent: WO 2005/061505 (2005-07-01), None
patent: WO 2005/061507 (2005-07-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Ferrarini et al., Bioorg. & Medicinal Chem., vol. 12 (2004), pp. 1921-1933, “Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors”.
Lange et al., Current Opin. in Drug Discovery & Develop., vol. 7 (2004), pp. 498-506, “Recent advances in CB1 cannabinoid receptor antagonists”.
Pertwee, Exp. Opin. Invest. Drugs, vol. 9 (2000), pp. 1553-1571, “Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development”.
Pertwee, Addiction Biology, vol. 5 (2000), pp. 37-46, “Neuropharmacology and therapeutic potential of cannabinoids”.
Evens et al., American Chem. Society, vol. 12 (1979), Poly(1,8-naphthyridines) and 1,9,10-anthyridines: Model systems for “Black Orlon”.

Affiliated with

Also associated with

Rating

Substituted naphthyridinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted naphthyridinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted naphthyridinone derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4237105